Pet Cancer Therapeutics Market Report 2021-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Pet Cancer Therapeutics industry overview and then goes into each and every detail.
Pet Cancer Therapeutics Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Pet Cancer Therapeutics also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1284
Pet Cancer, also known as nonmalignant neoplasia or malignancy, refers to the uncontrolled and unwanted growth of tissues. There are several kinds of pet cancer, therefore, it’s not just a single tumor. The medical term, tumor, would be a generic term for cancer regardless of whether it’s benign (good cancer) or malign (bad cancer). Animal healthcare is one of the most peculiar issues that require major awareness among pet owners. The prevalence of cancer in pets has increased significantly in the recent past. As per the American Veterinary Medical Association (AVMA), around 1 in 4 dogs will develop neoplasia at some stage in their life, while around 50% of dogs over aged 10 will develop cancer. Such a significant increase in cancer cases has surged the demand for cancer therapeutics. Hence, these factors can bolster growth of the pet cancer therapeutics market.
When it comes to geographical impact, North America seems to be gaining robust traction in the pet cancer therapeutics market. This could be due to growing cases of pet cancers and the presence of well-established healthcare facilities across the region. On the contrary, Asia Pacific is exhibiting a lucrative outlook due to rising awareness regarding animal healthcare in the region. Recently, in July 2021, VetDC Inc. received the U.S. Food and Drug Administration (FDA) approval for Tanovea to treat lymphoma in dogs.
One of the treatment options available is tumor staging. Tumor staging is used to determine if the tumor will require surgery or not. Depending upon the type of cancer, this can be done on an outpatient basis or in a hospital. Some cancers are inoperable (they cannot be removed) and are simply sent to the vet for removal. If the tumors appear to be malignant, they will have to undergo a more intensive surgical process. However, there are several factors that could pose major challenges in the development of the market. For instance, there are certain side-effects associated with pet cancer therapy such as nausea, vomiting, diarrhea, and a decrease in the white blood cell count. Besides, rising cost of animal testing, which could inhibit growth of the pet cancer therapeutics market.
Most commonly given as an initial treatment option for pet cancer, radiation is the most common. It is also given in a hospital setting. Radiation therapy uses high-energy radiation to kill cancer cells in a pet’s tumor without harming healthy cells. This is often combined with chemotherapy. Another factor augmenting the development of the said market is rising animal health awareness among pet owners. People have become significantly aware of different types of diseases associated with animals and thus are willing to spend more on animal healthcare and routine checkup. Therefore, such factors can potentially stimulate growth of the pet cancer therapeutics market.
Top Key Players Include In Pet Cancer Therapeutics Market: Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1284
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]
